TSHA vs. HHH, VCEL, AGIO, CGON, KNSA, BEAM, IDYA, IRON, BLTE, and CNTA
Should you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Howard Hughes (HHH), Vericel (VCEL), Agios Pharmaceuticals (AGIO), CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), and Centessa Pharmaceuticals (CNTA).
Taysha Gene Therapies vs. Its Competitors
Taysha Gene Therapies (NASDAQ:TSHA) and Howard Hughes (NYSE:HHH) are related companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.
In the previous week, Taysha Gene Therapies had 2 more articles in the media than Howard Hughes. MarketBeat recorded 8 mentions for Taysha Gene Therapies and 6 mentions for Howard Hughes. Howard Hughes' average media sentiment score of 0.76 beat Taysha Gene Therapies' score of 0.60 indicating that Howard Hughes is being referred to more favorably in the news media.
Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks.
Howard Hughes has a net margin of 14.27% compared to Taysha Gene Therapies' net margin of -1,201.08%. Howard Hughes' return on equity of 10.21% beat Taysha Gene Therapies' return on equity.
Taysha Gene Therapies has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Howard Hughes has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.
77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 93.8% of Howard Hughes shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 33.0% of Howard Hughes shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Taysha Gene Therapies currently has a consensus price target of $8.17, indicating a potential upside of 220.89%. Howard Hughes has a consensus price target of $80.33, indicating a potential upside of 16.44%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, research analysts plainly believe Taysha Gene Therapies is more favorable than Howard Hughes.
Summary
Howard Hughes beats Taysha Gene Therapies on 11 of the 16 factors compared between the two stocks.
Get Taysha Gene Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Taysha Gene Therapies Competitors List
Related Companies and Tools
This page (NASDAQ:TSHA) was last updated on 7/16/2025 by MarketBeat.com Staff
Free TSHA Stock Alerts